B+
Bull case
20%
Probability
Target price
$38.00
Analysis reference price unavailable
Analysis 2026-09-12 · RankAlpha Sentiment Codex
TCMD
TactileBNasdaq / Health Care Equipment & Services
Last Price
Quote time unavailable
AI scenario view
RankAlpha Sentiment CodexMost likely
B
Base case
50%
Probability
Target price
$26.00
Analysis reference price unavailable
Analysis 2026-09-12 · RankAlpha Sentiment Codex
B-
Bear case
30%
Probability
Target price
$17.00
Analysis reference price unavailable
Analysis 2026-09-12 · RankAlpha Sentiment Codex
The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented
AI sentiment snapshot
Latest data as of 2026-09-12
Recent news sentiment (30D)
+0.2
Mixed
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Weekly research (10D)
+30.0
Positive
Sentiment proxy
+82.7
Score
AI commentary
Recent coverage is mildly constructive around Q2 growth, margin expansion, and portfolio activity, but the AffloVest inventory issue tempers the tone. The $22.40 anchor is well below the August 10 insider transaction price, although the packet does not provide a reliable event-window return or attribute the decline to earnings. Social coverage, options skew, short interest, employee sentiment, and dependable post-print analyst revisions are unavailable; zero values in the sentiment object denote unavailable evidence rather than neutral readings.
RankAlpha Sentiment Codex - 2026-09-12
Open full AI memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-08-10catalystQ2 growth and profitability expansionMedium impact
Q2 revenue increased 9% year over year to $85.7 million, gross margin reached 76%, net income increased to $7.8 million, and adjusted EBITDA rose to $11.4 million. These reported results are encouraging but largely historical and likely substantially reflected in the stock. [#SEC-8K-2026-08-10]
2026-12-31eventAffloVest inventory normalizationHigh impact
The next-generation AffloVest was commercially launched, but airway-clearance revenue declined 7% year over year as several large DME partners managed inventory around the transition. Improved ordering could support a recovery, although management's more conservative segment outlook leaves the timing uncertain. [#SEC-8K-2026-08-10] [#PR-EARNINGS-2026-08-18]
2027-12-31catalystExpansion of the lymphedema care portfolioHigh impact
Lymphedema revenue grew 12% year over year to $73.6 million, while LymphaTech integration, MyoSleeve distribution rights for VA and DoD channels, and published Flexitouch Plus clinical results broaden the company's patient and provider reach. Sustained commercial execution could support profitable growth, but adoption evidence remains early. [#SEC-8K-2026-08-10]
Recommendation
N/A
No formal recommendation provided.
As of 2026-09-12 • Updated nightlySource: Internal modelMethodology